fbpx

News

Lundbeckfonden Ventures News

EO2401 combines three ‘OncoMimics’ designed to trigger the immune system into recognizing tumor cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response First patient dosed in Phase 1/2 (‘ROSALIE’) trial investigating EO2401 Paris, France and Cambridge, MA, USA – July 30, 2020 ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 27 July 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), announces that the US Food and Drug Administration (FDA) has approved of a second supplier for...
–    FDA has agreed to key aspects of the clinical program, including the primary endpoint for the single pivotal phase 3 study –    There are approximately 175,000 and 150,000 ESKD patients with PAD in the USA and Europe respectively with no approved treatments Palma, Spain and San Diego, USA, 20 July 2020 – Sanifit, a clinical-stage biopharmaceutical company developing...
Cambridge, UK and Indianapolis, US – 16 July 2020: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that application has been made to Euronext Brussels...
Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 15 July 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical...
After Discussions with FDA, NDA Submission Planned for 3Q 2020 under Accelerated Approval Pathway  Reltecimod in conjunction with currently available standard of care demonstrated a significant difference in the percentage of patients who achieved resolution of organ dysfunction/failure by Day 14 versus standard of care alone  Resolution of organ dysfunction/failure at Day 14...
Financing co-led by Ysios Capital and INKEF Capital, joined by Lundbeckfonden Ventures, LSP, and existing investors BioGeneration Ventures and InnovationQuarter • Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-C001, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program Leiden, The Netherlands,...
BURLINGTON, Mass. – July 1, 2020 – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and...
Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation   BYFAVO is a very rapid onset/offset IV benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy Approximately 25 million such procedures take place annually in the...
1 2 3 66

Lundbeckfonden Ventures

News

Enterome initiates first clinical trial with EO2401 – an innovative microbiome-antigen (‘OncoMimic’) based cancer immunotherapy candidate targeting aggressive brain cancer
30. July 2020
Acacia Pharma Advances Preparations for US Launch of BARHEMSYS® Second API Supplier for BARHEMSYS® Receives FDA Approval
27. July 2020
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
20. July 2020